Longevity & AgingAI Is Reshaping Neuromuscular Disease Care, but Most Tools Remain Unvalidated
This narrative review covers 2018–2025 literature on AI in neuromuscular diseases (NMDs), a group of over 800 mostly rare disorders. AI tools show high performance in variant interpretation, muscle MRI, EMG, pathology, proteomics and prognosis. A wearable endpoint (SV95C) has FDA/EMA qualification for Duchenne trials, and the ENCALS ALS survival model was validated across 14 European centers. However, most models were built and tested on single-center data, few have external or prospective validation, and research concentrates in ALS and Duchenne while conditions like myotonic dystrophy and congenital myopathies are nearly untouched. Federated learning, international networks and foundation models are proposed to close the gaps. This is a review, not new data, with no formal bias appraisal.